introduction: epidemiology of pancreatic...

39

Upload: others

Post on 20-Oct-2020

3 views

Category:

Documents


0 download

TRANSCRIPT

  • Pancreas exocrin

    › Pancreatite acute

    › Pancreatite cronice

    › Afectiuni ereditare ale pancreasului

    › Tumori pancreatice

    Pancreas endocrin

    › Diabetul zaharat

    › Tumorile neuroendocrine PET-NET

  • Pancreas exocrin

    › Pancreatite acute

    › Pancreatite cronice

    › Afectiuni ereditare ale pancreasului

    › Tumori pancreatice

    Pancreas endocrin

    › Diabetul zaharat

    › Tumorile neuroendocrine PET-NET

  • 4

    Pancreatita acuta

    urgenta

    garda UPU

    Chirurg sau

    Internist

    Pancreatita cronica

    durere abdominala trenanta

    Medic de familie !

    Eventual internist din policlinica

    Tumori pancreatice

    Nutritionist, medic de familie, endocrinolog, psihiatru, gastroenterolog

  • 5

    Necesita explorari

    Uneori sofisticate

    Necesara internare

    De obicei

    gastroenterolog

  • Incidenta 4,9-35 %ooo /an

    In crestere in tarile europene

    Cauza majora de spitalizare in SUA

    Cauza = crester consum de alcool

    Mortalitate 5- 17%

    Vege SS et al Gastrointestinal epidmiology 2007

  • Incidence of AP increased between 2000 and 2005 from 13.2 to 14.7

    Incidence of AP for males increased from 13.8 to 15.2, for females from 12.7 to 14.2

    Mortality for AP fluctuated between 6.9 and 11.7 per million

    persons/ year and was almost similar for males and females. Incidence and mortality of AP and CP increased markedly with age. CONCLUSION: Incidence of AP steadily increased. Mortality for AP remained fairly stable. Patient burden and health care costs probably will increase

    because of an ageing

    BW Ml Spanier et alWorld J Gastroenterol 2013 May 28; 19(20): 3018-3026

  • European studies increase in the incidence rate of acute pancreatitis

    922 patients with confirmed diagnosis of AP ( (2000–2009)in 1 hospital incidence rate varied from 24 to 35/100 000 inhabitants annually. Mean age was 60 ± 16 years. 53% men and 47% women etiologies of AP were biliary stones in 60% and alcohol abuse in 19%

    of patients. severe in 50% and 43 Davor Stimac et al - Gastroenterology Research and Practice

    Volume 2013, Article ID 956149,

  • Cauza › Pancreatita cronica

    › Fibroza chistica

    › Chirurgia pancreatica

    Prevalenta 3,9/100.000 EU › 3,3/100.000 Franta

    › 4,2 /100000 Germania

    › 2,9/100000 Italia

    › 3.0/100000 Spania

    › 5,5/100000 UK

    Mattson,Jakc Report 2005- Pancreatic exocrine insuffiency epidemiology

  • › Loss of functioning parenchyma Chronic pancreatitis Cystic Fibrosis Tumours Resections

    › ↓secretion despite intact parenchyma Obstruction ↓endogenous stimulation (coeliac, Crohns, DM)

    › Asynchrony Gastric resections Short bowel syndrome Crohns, DM

    › Enzyme inactivation Zollinger-Ellison syndrome

  • Prevalenta

    › Creste cu varsta

    › Mai mare la barbati

    Distributia pe sex si varsta difera f de etiologie

    › Alcoolica mai frecv la Barbati

    › Idiopatica si hiperlipemica la femei

    › Fiborza chistica egala femei barbati

    › Fibroza chistica mai frecv in primul an de viata

    › Pancreatita cronica si chirurgie la varstnic Rothenbacher D, etal Scand J Gast 2005;40(6)

  • Insuficienta pancreatica exocrina

    Pancreatectomie

    Rezectie

    gastrica

    Pancreatita

    cronica

    Pancreatita

    acuta

    Fibroza

    chistica

    “Pancreatita

    senila”

    Plenitudine Meteorism

    Intoleranta

    alimentelor

    Steatoree

    Pierdere in

    greutate

    Dispepsie

    Malabsortie

    Durere

    abdominala

    Greata / varsaturi Pierderea apetitului

    PEI

    Cauze

    Indicatie

    Semne

    simptome

  • Pancreatita cronica

    Incidenta PC este de 3,5 - 4 /

    100 000 locuitori.

    Prevalenta/Predominanta de

    vârsta si sex: pancreatita

    cronica afecteaza

    preponderent barbatii în vârsta

    de 35 - 45 ani (de 3 ori mai

    frecventa decât la femei).

    Forma usoara Forma severa Pseudochist

    Recidiva

    Restitutio ad integrum

    PA

    PC

    PA Pancreatita acuta

    PC Pancreatita cronica

    Klöppel & Maillet, Hepatogastroenterol 38:408, 1991

  • 14

    INCIDENTA = 3-10 %ooo loc

    PREVALENTA = 5.5-30 %ooo loc

    !!Este in crestere

    Variaza geografic

    Tara Incidenta

    /100 000 loc

    Sursa

    Japonia 5.7 JGastroenterol

    38(4):315-26, 2003

    Elvetia 1.6 Eur J Gastroenterol

    Hepatol.13(6):749-

    50, 2001

    Finlanda

    23 Pancreatology.2(5):

    469-77, 2002

    Cehia 7.9 idem

  • Inciența este de 6-7 /100.000 locuitori în vest

    80% sex masculin.

    Vârsta medie depinde de etiologie,

    › ~ 40-45 ani la PC alcoolică,

    › ~ 25-30 la PC idiopatică,

    › ~ 15-20 la cei PC ereditară,

    › ~ 10 ani la copii cu PC tropicală.

    Incidența este crescută la negri față de albi.

    James Jupp a,1, David Fine b,2, ColinD.Johnson c,*Best

    Practice&ResearchClinicalGastroenterology24(2010)219e231

  • Etiologie.

    Consumul excesiv de alcool 70-85%

    Fumatul, l factor de risc extern cancerului pancreatic.

    Alte cauze rare de PC:

    hipercalcemia peste 12mg/dl (3mmol/l (1% din PC sunt datorate hiperPTH, 7% din hiperPTH au și PC).

    PC tropicală.

    PC genetică.

    PC autoimună

    PC obstructivă.

    PC idiopatică. 10% din cazurile de PC

    James Jupp a,1, David Fine b,2, ColinD.Johnson c,*Best

    Practice&ResearchClinicalGastroenterology24(2010)219e231

  • Benigne

    Maligne

    Epiteliale

    Nonepiteliale

    Exocrine

    Endocrine

  • Epithelial tumours Benign Serous cystadenoma 8441/01 Mucinous cystadenoma 8470/0 Intraductal papillary-mucinous adenoma 8453/0 Mature teratoma 9080/0 Borderline (uncertain malignant potential) Mucinous cystic neoplasm with moderate dysplasia 8470/1 Intraductal papillary-mucinous neoplasm with moderate dysplasia Solid-pseudopapillary neoplasm 8452/1 Malignant Ductal adenocarcinoma 8500/3 Mucinous noncystic carcinoma 8480/3

    Signet ring cell carcinoma 8490/3 Adenosquamous carcinoma 8560/3 Undifferentiated (anaplastic) carcinoma 8020/3 Undifferentiated carcinoma with osteoclast-like giant cells 8035/3 Mixed ductal-endocrine carcinoma 8154/3 Serous cystadenocarcinoma 8441/3 Mucinous cystadenocarcinoma 8470/3 – non-invasive 8470/2

    – invasive 8470/3 Intraductal papillary-mucinous carcinoma 8453/3 – non-invasive 8453/2 – invasive (papillary-mucinous carcinoma) 8453/3

    Acinar cell carcinoma 8550/3 Acinar cell cystadenocarcinoma 8551/3 Mixed acinar-endocrine carcinoma 8154/3 Pancreatoblastoma 8971/3

    Solid-pseudopapillary carcinoma 8452/3

    Others

    Non-epithelial tumours

    Secondary tumours

  • Primary Tumour (T) TX Primary tumour cannot be assessed T0 No evidence of primary tumour Tis Carcinoma in situ T1 Tumour limited to the pancreas, 2 cm or less in greatest

    dimension T2 Tumour limited to the pancreas, more than 2 cm in

    greatest dimension T3 Tumour extends directly into any of the following:

    duodenum, bile duct, peripancreatic tissues3 T4 Tumour extends directly into any of the following:

    stomach, spleen, colon, adjacent large vessels4 Regional Lymph Nodes (N) NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Regional lymph node metastasis N1a Metastasis in a single regional lymph node N1b Metastasis in multiple regional lymph nodes Distant Metastasis (M) MX Distant metastasis cannot be assessed M0 No distant metastasis MI Distant metastasis

    Stage grouping Stage 0 Tis N0 M0

    Stage I T1 N0 M0

    T2 N0 M0

    Stage II T3 N0 M0

    Stage III T1 N1 M0

    T2 N1 M0

    T3 N1 M0

    Stage IVA T4 Any N M0

    Stage IVB Any T Any N M1

  • Sex Cancer Recorded deaths 2007 Predicted number of deaths 2012

    Men

    Stomach 37424 33926

    colon and rectum 85244 89117

    Pancreas 35022 39088

    Lung 183019 183592

    Prostate 68282 69960

    Leukemias 21553 22320

    All cancers (malignant and benign) 706619 717398

    Women

    Stomach 25060 21138

    Colon and rectum 75294 73989

    Pancreas 34965 38443

    Lung 69115 78658

    Breast 89012 88101

    Uterus (cervix and corpus) 27393 26720

    Leukemias 17884 18605

    All cancers (malignant and benign)554515 565703

    Malvezi M et al - Annals of Oncology 28 feb 2012

  • 10th most frequent cancer

    the 8th leading cause of cancer-related

    death

    Incidence

    men: 7,3 – 8,7 per 100.000

    women: 4,5 – 5,7 per 100.000

    >95% of patients are dying of their disease

    No survival increases have been observed

    in the last years

    S. Cascinu et al. Annals of Oncology 21 (Supplement 5): v55–v58,

    2010

  • Demographic factors Old age (most reliable and important predictor) Sex (more common in males than in females) Ethnic origin (mortality highest in black populations)

    Genetic factors and medical conditions Family history (one first degree → 2,3 fold increased risk) Hereditary pancreatitis Hereditary non-polyposis colorectal cancer Ataxia-telangiectasia Peutz-Jeghers syndrome (132 fold increased risk) Familial breast cancer (BRCA2 mutations) Familial atypical multiple mole melanoma (germline mutations in p16) Chronic pancreatitis (2% per decade) Diabetic mellitus Gastrectomy

    Deficiency in carcinogen metabolism and DNA repair Environmental and lifestyle factors Cigarette smoking Occupational exposures Low dietary intake of fruits and vegetables Food preparation and cooking methods (grilling or charring confers the highest risk)

    James L Abbruzzese et al. Lancet 2004; 363: 1049–57

  • Enviromental factors

    cigarette smoking* RR = at least 1,5

    especially in smokers with GSTT1 (homozygous deletions of

    gene glutathione S-transferase T1)

    risk level returns to baseline by 15 years after cessation

    dietary** excessive fat or meat

    diabetes mellitus*** diagnosed within the preceding two years

    associated with obesity

    *Ghadirian P. Cancer 1991; 67:2664-70

    **Farrow DC. Am J Epidemiol 1990; 132:423-31

    ***Gullo L. N Engl J Med 1994; 331:81-4

  • Normal pancreas has 3 types of epithelial cells Acinar cells – 80%

    Ductal cells – 10-15%

    Endocrine cells -

  • Benign Serous cystadenoma Mucinous cystadenoma Intraductal papillary mucinous adenoma Mature cystic teratoma

    Borderline (uncertain malignant potential) Mucinous cystic tumor with moderate dysplasia Intraductal papillary mucinous tumor with moderate dysplasia Solid-pseudopapillary tumor

    Malignant Ductal adenocarcinoma Osteoclast-like giant cell tumor Serous cystadenocarcinoma Mucinous cystadenocarcinoma (noninvasive or invasive) Intraductal papillary mucinous carcinoma (noninvasive or

    invasive) Acinar cell carcinoma Pancreatoblastoma Solid-pseudopapillary carcinoma Miscellaneous carcinomas

    Hamilton SR, Aaltonen LA. World Health Organization Classification of Tumours.

    Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC

    Press; 2000

  • successive accumulation of gene mutations

    3 precursor lesions*:

    › Primary histologic precursor of pancreatic cancer =

    pancreatic intraductal neoplasia (PanIN)

    PanIN 1a,b (minimally dysplastic epithelium) ** activation of the KRAS2 oncogene, inactivation of the tumor-suppressor gene CDKN2A

    inactivation of the tumor-suppressor genes TP53 and deleted in

    pancreatic

    cancer 4 (DPC4, also known as the SMAD4

    PanIN 2,3 (severe dysplasia)

    › Mucinous cystic neoplasm (MCN)

    › intraductal pancreatic mucinous neoplasm (IPMN)

    * Jason Klapman. Cancer Control October 2008, Vol. 15, No. 4 ** Feldmann G. J Hepatobiliary Pancreat Surg 2007;14:224-32

  • Normal duct

    Normal duct

    PanIN Ia PanIN Ib PanIN II PanIN III

    MCN low grade

    IPMN low grade

    Intermediate grade

    High grade

    Cancer

    Jason Klapman. Cancer Control October 2008, Vol. 15, No. 4

  • Gene/ chromosomal region

    (oncogenes and tumor supression)

    % of tumors with genetic mutation

    K-ras (12p) >90%

    p16 CDKN2A (9p) >95%

    PK53 (17p) 50%-70%

    SMAD4/DPC4 (18q) 55%

    AKT2 (19q) 10%-20%

    MYB (6q) 10%

    AIB1 (20q) 10%

    BRCA2 (13q) 7%-10%

    LKB1/STK11 (19p)

  • Oncogenes – K-ras present in 90% of cancers

    frequency of mutations = extent of dysplasia

    Can be detected in chronic pancreatitis without neoplasia

    Tumor suppressor genes TP53 mutations → chromosomal instability → cancer

    P16 mutation

    associated with FAMMM syndrome (melanoma and pancreatic cancer)

    associated with decreased survival

    DPC4 = effect on cell cycle regulation and cell differentiation

    Other: up-regulation of EGF, telomere shortening

  • Cancer Incidence

    Oesophagus 578

    Stomach 2650

    Colorectum 4554

    Liver 1279

    Gallbladder 293

    Pancreas 1682

    Lung 8387

    Prostate 3620

  • Cancer Incidence Oesophagus 103

    Stomach 1351 Colorectum 4142 Liver 692

    Gallbladder 355 Pancreas 1184 Breast 7929 Cervix uteri 3402 Corpus uteri 1208 Ovary 1686

  • Male Female both

    Lung Breast Lung

    Colorectum Colorectum Colorectum

    Prostate Cervix uteri Breast

    Stomach Lung Stomach

    Bladder Ovary Prostate

    Romania GLOBOCAN 2008

  • Statisitica MS – PCR in 2011 – 975 cazuri = 4,8 %ooo locuitori

    Studii › Diculescu et al –Romanian J gastroenterol 2005 –

    studiu de cohorta PAC – 62 pacienti sp Elias

    › Hajjar N et al – Chirurgia 2012 – 81 pacienti Chirurgie 3 Cluj

    › Hecser L et al – Rom J Legal Med2009 – case reports PAC

    › Diaconu B – J Gastrointest Liver Disease 2009 –SPINK 1 mutatie in 94 pac cu PCR

  • Cauze

    › Raportarea in functie de ICM/DRG modifica

    formularea diagnostica

    › Raportarea in teritoriu deficitara

    › Patologie complexa ce implica multe

    esaloane medicale ( primara, secundara

    tertiare) fiecare cu raportari diferite

  • Dezavantaje

    › Simptomatologia in patologia pancreatica apare de f multe ori f tardiv in stadii avansate

    › Diagnosticul se bazeaza pe explorari imagistice sofisticate inabordabila pt metode de screening

    “Avantaje”

    › Pancreatitele acute se interneaza doar in spitalele de urgenta

    › Rata incidentei in tumorile maligne pancreatica este practic egala cu cea a mortalitatii

    › Putine cazuri de Pancreatite cronice

  • Abord multidiscliplinar

    Standardizarea diagnosticelor

    APPR => registre pe domenii restranse

    de cazuri

    › Pancreatite ereditare

    › Tumori pancreatice rare

    › Tumori neuroendocrine (PET-NET)

  • Incidenta pancreatitelor acute este in

    crestere in tarile occidentale ( si la noi?)

    Cunoasterea corecta a abordarii PAC poate

    salva vieti

    Pancreatitele cronice sunt subdiagnosticate si

    subestimate

    Tumorile pancreatice sunt in crestere si nu

    sunt metode de screening eficient actual